ID: h-c42d677719
Hypothesis
A lower trazodone dose of 50-100 mg nightly may be sufficient only in dementia patients with marked slow-wave sleep deficiency
A lower effective dose may exist in a sleep-fragmented subgroup if the beneficial mechanism is indirect, via improved slow-wave sleep rather than direct ISR rescue.
EvidencePending (0%)📖 0 cit🗣 1 debates✓ 4 support✗ 3 oppose
🧪 Overview
A lower effective dose may exist in a sleep-fragmented subgroup if the beneficial mechanism is indirect, via improved slow-wave sleep rather than direct ISR rescue. This is clinically feasible and testable, but current support is stronger for symptomatic sleep benefit than for true disease modification.
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
flowchart TD
A["CSF Arterial Inflow<br/>Periarterial Space"]
B["AQP4 on Astrocyte Endfeet<br/>Perivascular Polarization"]
C["Glymphatic Flow<br/>ISF Convective Clearance"]
D["Abeta/Tau Efflux<br/>Perivenous Drainage"]
E["Lymphatic Outflow<br/>Cervical Lymph Nodes"]
F["AQP4 Mislocalization<br/>in AD/Aging"]
G["Reduced ISF Clearance<br/>Aggregate Accumulation"]
A --> B
B --> C
C --> D
D --> E
F -.->|"impairs"| C
F --> G
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style D fill:#1b5e20,stroke:#81c784,color:#81c784
style F fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style G fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a⚖️ Evidence
⚖️ Evidence Matrix4 supports3 contradicts
Supports
Low-dose trazodone improved sleep parameters in patients with AD, supporting a deployable sleep-architecture mechanism.
Supports
Acute sleep loss and disruption increase amyloid-beta and tau-related biomarkers in humans.
Supports
Slow-wave sleep loss predicts incident dementia, supporting subgroup enrichment by sleep phenotype.
Contradicts
Existing trazodone sleep trials in AD were short and did not demonstrate disease modification.
Contradicts
The glymphatic and sleep-to-neuroprotection bridge remains indirect and partly speculative in humans.
Contradicts
Any observed benefit could reflect symptomatic improvement, reduced agitation, or caregiver-reported function rather than slowed neurodegeneration.
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — HTR2A;
No curated PDB or AlphaFold mapping for HTR2A; yet. Search RCSB →
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for HTR2A; HRH1; AQP4 from GTEx v10.
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for HTR2A; HRH1; AQP4.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▲ 0.0%
Volatility
High
0.0730
Events (7d)
1
Price History
▼2.6%💾 Resource Usage
No resource usage or linked notebooks recorded for this hypothesis yet.
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF trazodone 50-100mg nightly is administered to Alzheimer's disease patients with PSG-confirmed marked slow-wave sleep deficiency (NREM stage 3 < 10% of total sleep time), THEN their slow-wave sleep | Mean NREM stage 3 percentage increases from baseline <10% to ≥15% in the SWS-deficient group | — no observation — | pending | 0.35 |
| IF the dose-response relationship for sleep improvement is subgroup-dependent, THEN Alzheimer's disease patients with marked SWS deficiency (<10% NREM3 at baseline) will show clinically meaningful imp | PSQI reduction ≥3 points in ≥60% of SWS-deficient patients versus <30% of non-deficient patients at 50-100mg trazodone | — no observation — | pending | 0.30 |
🔮 Falsifiable Predictions (2)
pendingconf 35%
IF trazodone 50-100mg nightly is administered to Alzheimer's disease patients with PSG-confirmed marked slow-wave sleep deficiency (NREM stage 3 < 10% of total sleep time), THEN their slow-wave sleep percentage will increase by at least 5 absolute percentage points within 4 weeks of treatment.
Predicted outcome: Mean NREM stage 3 percentage increases from baseline <10% to ≥15% in the SWS-deficient group
Falsification: No statistically significant increase in NREM stage 3 percentage (p > 0.05) or absolute increase < 5 percentage points in the marked SWS-deficient subgroup after 4 weeks of low-dose trazodone
pendingconf 30%
IF the dose-response relationship for sleep improvement is subgroup-dependent, THEN Alzheimer's disease patients with marked SWS deficiency (<10% NREM3 at baseline) will show clinically meaningful improvement in Pittsburgh Sleep Quality Index (PSQI reduction ≥3 points) at trazodone 50-100mg, while p
Predicted outcome: PSQI reduction ≥3 points in ≥60% of SWS-deficient patients versus <30% of non-deficient patients at 50-100mg trazodone
Falsification: Non-markedly deficient patients (baseline NREM3 ≥10%) demonstrate equal or greater PSQI improvement (≥3 point reduction) as the SWS-deficient subgroup at 50-100mg trazodone, indicating dose-requiremen
▸Metadatasource: v1_phase_c_backfill · origin_type: gap_debate
| source | v1_phase_c_backfill |
| origin_type | gap_debate |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.